The FDA Introduces Naming Conventions for Biosimilars
9/
02
The FDA Introduces Naming Conventions for Biosimilars
Patient advocacy groups are praising the FDA for releasing a draft guidance that outlines the FDA’s proposed guidelines for naming biologics and biosimilars.
A distinctive naming convention was needed to clearly identify biological products to improve pharmacovigilance and to clearly differentiate among biological products that have not been determined to be interchangeable, the FDA stated.